HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Like Other Outbreaks, Coronavirus Symptoms Include False Health Claims, Price-Gouging

Executive Summary

FDA isn't alone monitoring drug, medical device and food companies making false Covid-19 treatment claims. New York AG warns Jim Bakker, UK agency cuts off face mask ads, Amazon removes thousands of products priced to cheat fearful consumers and Facebook cuts false ads.

You may also be interested in...



Amazon Flexes E-Commerce Heft By Imposing Quality-Control Requirements For Supplements

Amazon requires firms selling supplements on its site in the US to demonstrate their products comply with FDA regulations for labeling and GMPs. Marketers that don’t submit documentation face removal of their products from the site.

COVID-19 Fraud In US: Online Pharmacies Promote HIV Drug, Ammo Dealer Pitches Vitamin C

Latest letters from website reviews push to 62 the number of warnings the FDA, either jointly with the FTC or on its own, has made stating that no drug has yet been approved by the agency for use in the prevention, diagnosis, treatment, mitigation or cure of COVID-19.

COVID-19 Magnifies US Need To Make Supplements Eligible For Pre-Tax Savings – NPA

NPA asks Congress to include supplements in legislation defining "medical expenses” covered by pre-tax health savings accounts. The trade group says industry would prefer supplements were included with OTC drugs in provision in recently passed COVID-19 relief legislation that changed pre-tax account rules.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel